Literature DB >> 14685159

Do cells need CDK2 and ... Bcr-Abl?

M V Blagosklonny1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14685159     DOI： 10.1038/sj.cdd.4401361

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  9 in total

1.  NCI's provocative questions on cancer: some answers to ignite discussion.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2011-12

2.  Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells.

Authors:  Sabina Honisch; Willi Yu; Guilai Liu; Ioana Alesutan; Syeda T Towhid; Anna Tsapara; Sabine Schleicher; Rupert Handgretinger; Christos Stournaras; Florian Lang
Journal:  Oncotarget       Date:  2015-04-30

3.  Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.

Authors:  Yingying Shen; Xiaomei Ren; Ke Ding; Zhang Zhang; Deping Wang; Jingxuan Pan
Journal:  Oncotarget       Date:  2014-11-15

4.  Anti-apoptotic effects of PCP4/PEP19 in human breast cancer cell lines: a novel oncotarget.

Authors:  Taiji Hamada; Masakazu Souda; Takuya Yoshimura; Shoko Sasaguri; Kazuhito Hatanaka; Takashi Tasaki; Takako Yoshioka; Yasuyo Ohi; Sohsuke Yamada; Masato Tsutsui; Yoshihisa Umekita; Akihide Tanimoto
Journal:  Oncotarget       Date:  2014-08-15

5.  The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.

Authors:  Martina Olivero; Daniela Dettori; Sabrina Arena; Davide Zecchin; Erica Lantelme; Maria Flavia Di Renzo
Journal:  Oncotarget       Date:  2014-08-15

6.  Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Authors:  María Jesús Ortiz-Ruiz; Stela Álvarez-Fernández; Tracy Parrott; Sara Zaknoen; Francis J Burrows; Alberto Ocaña; Atanasio Pandiella; Azucena Esparís-Ogando
Journal:  Oncotarget       Date:  2014-11-30

7.  Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.

Authors:  Liu Yang; Dongdong Fang; Huijun Chen; Yiyu Lu; Zheng Dong; Han-Fei Ding; Qing Jing; Shi-Bing Su; Shuang Huang
Journal:  Oncotarget       Date:  2015-08-28

8.  Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia.

Authors:  Sabrina Copsel; Ariana Bruzzone; Maria May; Julien Beyrath; Victoria Wargon; Jeannette Cany; Frans G M Russel; Carina Shayo; Carlos Davio
Journal:  Oncotarget       Date:  2014-10-15

9.  Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Authors:  Sue Ellen Verbrugge; Marjon Al; Yehuda G Assaraf; Sarah Kammerer; Durga M S H Chandrupatla; Richard Honeywell; Rene P J Musters; Elisa Giovannetti; Tom O'Toole; George L Scheffer; David Krige; Tanja D de Gruijl; Hans W M Niessen; Willem F Lems; Pieternella A Kramer; Rik J Scheper; Jacqueline Cloos; Gert J Ossenkoppele; Godefridus J Peters; Gerrit Jansen
Journal:  Oncotarget       Date:  2016-02-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.